Austrian authorities have suspended inoculations with a batch of AstraZeneca's Covid-19 vaccine as a precaution while investigating the death of a woman and the illness of another after the shots, a health agency said on Sunday.
"The Federal Office for Safety in Health Care has received two reports in a temporal connection with a vaccination from the same batch of the AstraZeneca vaccine in the district clinic of Zwettl" in Lower Austria province, it said.
The woman, 49, died as a result of severe coagulation disorders, while the other, 35, developed a pulmonary embolism and is recovering, it said.
A pulmonary embolism is an acute lung disease caused by a dislodged blood clot.
"Currently there is no evidence of a causal relationship with the vaccination," the office said.
Austrian media reported that the women were both nurses who worked at the Zwettl clinic.
The office said blood clotting was not among the known side effects of the vaccine.
It was pursuing its investigation vigorously to completely rule out any possible link.
"As a precautionary measure, the remaining stocks of the affected vaccine batch are no longer being issued or vaccinated," it said.
An AstraZeneca spokesman said: "There have been no confirmed serious adverse events associated with the vaccine."
He said all batches were subject to strict and rigorous quality controls.
Trials and real-world experience so far suggests the vaccine is safe and effective, and it had been approved for use in more than 50 countries, he said.
AstraZeneca also said it was in contact with Austrian authorities and would fully support the investigation.
EU regulators at the end of January approved the product, saying it was effective and safe to use, while the World Health Organisation in mid-February listed the product for emergency use.
Adverse reactions seen in trials were short-lived for the most part and blood-clotting problems were not reported.
A safety assessment by Germany’s vaccine regulator of more than 360,000 people who received the Astra vaccine in the country between the launch in early February and February 26 concluded that adverse reactions were in line with the safety profile described in clinical trials.
